Literature DB >> 32683733

A humanized antibody inhibitor for cathepsin L.

Xiaojing Shi1, Yong Zhang1,2,3,4.   

Abstract

Cathepsin L (CTSL) is a cysteine protease involved in a variety of physiological and pathological processes. Potent inhibitors against CTSL have long been sought for drug development. Due to insufficient specificity and suboptimal pharmacological properties for current CTSL inhibitors, novel agents are still required for selectively blocking CTSL activity. Here we generated a humanized antibody inhibitor of CTSL by genetically fusing the inhibitory propeptide of procathepsin L to the N-terminus of the light chain of a humanized antibody. The resulting antibody fusion could be stably expressed and displays highly potent inhibition activity and specificity toward CTSL. This work demonstrates a new approach for the rapid generation of antibody inhibitors of CTSL. It can possibly be extended to create inhibitory antibodies targeting other cathepsin proteases, providing novel research and therapeutic tools.
© 2020 The Protein Society.

Entities:  

Keywords:  antibody; cathepsin L; protease inhibitor; protein engineering

Mesh:

Substances:

Year:  2020        PMID: 32683733      PMCID: PMC7454522          DOI: 10.1002/pro.3913

Source DB:  PubMed          Journal:  Protein Sci        ISSN: 0961-8368            Impact factor:   6.725


  25 in total

Review 1.  Cysteine cathepsins in extracellular matrix remodeling: Extracellular matrix degradation and beyond.

Authors:  Matej Vizovišek; Marko Fonović; Boris Turk
Journal:  Matrix Biol       Date:  2018-02-01       Impact factor: 11.583

2.  Transition state analogues of Plasmodium falciparum and human orotate phosphoribosyltransferases.

Authors:  Yong Zhang; Gary B Evans; Keith Clinch; Douglas R Crump; Lawrence D Harris; Richard F G Fröhlich; Peter C Tyler; Keith Z Hazleton; María B Cassera; Vern L Schramm
Journal:  J Biol Chem       Date:  2013-10-24       Impact factor: 5.157

Review 3.  Cysteine protease cathepsins in cardiovascular disease: from basic research to clinical trials.

Authors:  Cong-Lin Liu; Junli Guo; Xian Zhang; Galina K Sukhova; Peter Libby; Guo-Ping Shi
Journal:  Nat Rev Cardiol       Date:  2018-06       Impact factor: 32.419

4.  Rational design of a humanized glucagon-like peptide-1 receptor agonist antibody.

Authors:  Yong Zhang; Huafei Zou; Ying Wang; Dawna Caballero; Jose Gonzalez; Elizabeth Chao; Gus Welzel; Weijun Shen; Danling Wang; Peter G Schultz; Feng Wang
Journal:  Angew Chem Int Ed Engl       Date:  2014-12-29       Impact factor: 15.336

5.  Potency and selectivity of inhibition of cathepsin K, L and S by their respective propeptides.

Authors:  J Guay; J P Falgueyret; A Ducret; M D Percival; J A Mancini
Journal:  Eur J Biochem       Date:  2000-10

6.  Recombinant cathepsin S propeptide attenuates cell invasion by inhibition of cathepsin L-like proteases in tumor microenvironment.

Authors:  Roberta E Burden; Philip Snoddy; Richard J Buick; James A Johnston; Brian Walker; Christopher J Scott
Journal:  Mol Cancer Ther       Date:  2008-03       Impact factor: 6.261

Review 7.  Cysteine cathepsin proteases as pharmacological targets in cancer.

Authors:  Carmela Palermo; Johanna A Joyce
Journal:  Trends Pharmacol Sci       Date:  2007-11-26       Impact factor: 14.819

8.  Rational Design of a Humanized Antibody Inhibitor of Cathepsin B.

Authors:  Zhefu Dai; Qinqin Cheng; Yong Zhang
Journal:  Biochemistry       Date:  2020-03-31       Impact factor: 3.162

9.  Updated guidance for palivizumab prophylaxis among infants and young children at increased risk of hospitalization for respiratory syncytial virus infection.

Authors: 
Journal:  Pediatrics       Date:  2014-08       Impact factor: 7.124

Review 10.  Cysteine Cathepsins in Tumor-Associated Immune Cells.

Authors:  Tanja Jakoš; Anja Pišlar; Anahid Jewett; Janko Kos
Journal:  Front Immunol       Date:  2019-08-28       Impact factor: 7.561

View more
  1 in total

1.  A humanized antibody inhibitor for cathepsin L.

Authors:  Xiaojing Shi; Yong Zhang
Journal:  Protein Sci       Date:  2020-08-07       Impact factor: 6.725

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.